AI-driven drug design for short-term anxiety disorder

Author:

S Hari Ram1,V Latha2,V Gomathi1,A Ranichitra2,Dhamotharan Varsha3,RM Vidhyavathi4,D Prabhu5

Affiliation:

1. National Engineering College

2. Sri S Ramasamy Naidu Memorial College

3. MEPCO Schlenk Engineering College

4. Alagappa University

5. Kalasalingam Academy of Research and Education

Abstract

Abstract

Anxiety is the most common neurological disorder and results in cognitive, emotional, and somatic behavioral changes. Anxiety may invoke an unpleasant feeling that is strongly associated with apprehension, fear, and disturbance of daily routine life activities. GABA acts as an inhibitory neurotransmitter within the central nervous system, and a decrease in its levels can result in anxiety. Therefore, GABA-A receptor proteins (PDB ID: 4COF) are suitable targets for drug design. Lorazepam is a commonly used drug for the treatment of short-term anxiety. However, Lorazepam causes serious side effects both physically and mentally during treatment for patients. To alleviate the serious side effects of Lorazepam, in this work, in silico studies based on modern artificial intelligence (AI)-based virtual screening were carried out with a series of computational chemistry methods, such as molecular docking (MD), molecular dynamics simulation (MDS) and quantitative structure–activity relationships (QSAR). Initially, using the MolAICal tool, compounds similar to Lorazepam were generated (M1-M12), and based on drug likeliness, 9 compounds were selected (M1, M4-M7, M9-M12). Then, molecular docking was carried out to analyze and visualize their binding scores with the 4COF protein structure. Compound M12 has a greater binding affinity (i.e., a lower binding energy of -8.276 kcal/mol) than Lorazepam. Its applicability was ascertained via QSAR analysis. A molecular dynamics study of M12 and that of Lorazepam showed that M12 has very good binding to the protein 4COF through multiple H-bond interactions, as more than 100% of the simulation times with the ASP 43 residue and 98% of the simulation times with the GLU155 residue. Various protein‒ligand interactions that lasted more than 48% of the simulation time in the selected trajectory were considered. Analysis of these parameters demonstrated the stable binding of M12 within the binding pocket of 4COF, and M12 had more interactions; hence, M12 was proven to be an alternative drug for treating anxiety with high efficacy.

Publisher

Research Square Platform LLC

Reference52 articles.

1. Marmot M (2010) Fair society, healthy lives: the Marmot Review : strategic review of health inequalities in England post, ISBN 9780956487001

2. A systematic review of reviews on the prevalence of anxiety disorders in adult populations;Remes O;Brain Behav,2016

3. Practice Guideline on Alcohol Withdrawal Management;The ASAM Clinical;J Addict Med,2020

4. Ativan (Lorazepam) (ed) (2012) J Addict Nurs. 23 141

5. Conversion factors for assessment of driving impairment after exposure to multiple benzodiazepines/z-hypnotics or opioids;Strand MC;Forensic Sci Int,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3